Clover Biopharmaceuticals, Ltd. (SEHK: 2197)
Health Care · Biotechnology · CN
HK$1.79
-12.71% today · -39.5% 1Y
Clover Biopharmaceuticals, Ltd. (SEHK: 2197) operates in the Biotechnology industry within the Health Care sector. The company is valued at $295.33M and employs 257 people.
Over the last twelve months the share price has lost 39.5%, trading between 1.32 and 3.20.
Tweenvest scores Clover Biopharmaceuticals, Ltd. across four factors: quality 24/100, value 75/100. Its strongest factor is value.
2197 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $295.33M
- Revenue (TTM)
- $63.30K
- P/E
- 2.32
- EPS
- 0.67
- Dividend yield
- —
- Beta (5Y)
- 2.58
- 52-week high
- HK$3.20
- 52-week low
- HK$1.32
- Avg volume (3M)
- —
- Shares outstanding
- 1.30B
- Employees
- 257
- Next earnings
- —
About Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
- ISIN
- KYG2280A1076
- Founded
- 2007
- Listed since
- Nov 5, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TCM Biotech International Corp.TWSE: 4169 | $306.45M | NT$147.50 | -2.64% |
| Perspective Therapeutics, Inc.NYSEAM: CATX | $303.64M | $2.66 | -1.85% |
| AprilBio Co.,Ltd.KOSDAQ: A397030 | $297.93M | ₩14,560.00 | -14.45% |
| Curocell Inc.KOSDAQ: A372320 | $296.19M | ₩26,150.00 | +13.70% |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $288.52M | $2.91 | +2.83% |
| CytoDyn Inc.OTCPK: CYDY | $287.21M | $0.20 | -11.89% |
| Eurobio Scientific Société anonymeENXTPA: ALERS | $284.09M | €25.20 | +0.40% |
| Abeona Therapeutics Inc.NasdaqCM: ABEO | $282.49M | $4.94 | -1.79% |
Figures last refreshed Oct 11, 2026.